executive name, CEO of company XYZ, sells 10,000 shares for $150,000 in insider transaction

executive sells $115,000 in [Company Name] stock

[CITY, STATE] – An executive at [Company Name] ([EXCHANGE:TICKER]) recently sold company stock totaling $115,000, according to a recent regulatory filing.

The transaction involved the sale of 5,000 shares of [Company Name] common stock at a price of $23.0 per share. The sale was executed on [Date of Transaction] by [Executive Name], who holds the position of [Executive Title] at the company. The sale occurred near the stock’s 52-week high of $23.15, following a remarkable 112% gain over the past year that has pushed the company’s market capitalization to $3.5 billion.

Footnote [1] in the filing indicated that [Footnote 1 text, e.g., "the shares were sold to cover tax obligations related to the vesting of restricted stock units."].

In other recent news, Adaptive Biotechnologies Corporation reported strong financial results for the first quarter of 2026, with revenue reaching $70.9 million, surpassing analyst expectations of $60.89 million. This revenue growth was primarily driven by the company’s Minimal Residual Disease business. Additionally, Adaptive Biotechnologies announced plans to offer $250 million in convertible senior notes due 2031, with an option for initial purchasers to acquire an additional $37.5 million in notes. The company intends to conduct this offering through a private placement to qualified institutional buyers. Furthermore, Adaptive Biotechnologies revealed its intention to separate its Minimal Residual Disease and Immune Medicine units, with a strategic decision expected by the end of 2026. BTIG reiterated a Buy rating on the company’s stock, maintaining a price target of $22.00, following these business updates. The firm highlighted the upsized convertible notes offering, which increased from $250 million to $300 million, and the planned business separation as key factors in its assessment.